<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Cardiothorac Surg</journal-id>
      <journal-title-group>
        <journal-title>Journal of Cardiothoracic Surgery</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1749-8090</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">20196861</article-id>
      <article-id pub-id-type="pmc">2843680</article-id>
      <article-id pub-id-type="publisher-id">1749-8090-5-9</article-id>
      <article-id pub-id-type="doi">10.1186/1749-8090-5-9</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Papadopoulos</surname>
            <given-names>Georgios</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>geopapad@cc.uoi.gr</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A2">
          <name>
            <surname>Baikoussis</surname>
            <given-names>Nikolaos G</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>ngbaik@yahoo.com</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Tzimas</surname>
            <given-names>Petros</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>petzimas@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Siminelakis</surname>
            <given-names>Stavros N</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>ssiminel@yahoo.gr</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Karanikolas</surname>
            <given-names>Menelaos</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>kmenelaos@yahoo.com</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Clinical Anaesthesiology and Intensive Postoperative Care Unit, University of Ioannina School of Medicine, Ioannina, Greece</aff>
      <aff id="I2"><label>2</label>Department of Cardiac Surgery, University of Ioannina School of Medicine, Ioannina, Greece</aff>
      <aff id="I3"><label>3</label>Department of Anaesthesiology and Critical Care Medicine, University of Patras School of Medicine, Patras, Greece</aff>
      <pub-date pub-type="collection">
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>2</day>
        <month>3</month>
        <year>2010</year>
      </pub-date>
      <volume>5</volume>
      <fpage>9</fpage>
      <lpage>9</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>1</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>3</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2010 Papadopoulos et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2010</copyright-year>
        <copyright-holder>Papadopoulos et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.cardiothoracicsurgery.org/content/5/1/9"/>
      <abstract>
        <p>This the case of a 63 year-old man with end-stage renal disease (on chronic hemodialysis), unstable angina and significantly impaired myocardial contractility with low left ventricular ejection fraction, who underwent off-pump one vessel coronary bypass surgery. Combined continuous levosimendan and norepinephrine infusion (at 0.07 &#x3BC;g/kg/min and 0.05 &#x3BC;g/kg/min respectively) started immediately after anesthesia induction and continued for 24 hours. The levosimendan/norepinephrine combination helped maintain an appropriate hemodynamic profile, thereby contributing to uneventful completion of surgery and postoperative hemodynamic stability. Although levosimendan is considered contraindicated in ESRD patients, this case report suggests that combined perioperative levosimendan/norepinephrine administration can be useful in carefully selected hemodialysis patients with impaired myocardial contractility and ongoing myocardial ischemia, who undergo off-pump myocardial revascularization surgery.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Levosimendan (OR 1259), the levo-isomer of racemic simendan [<xref ref-type="bibr" rid="B1">1</xref>] is a pharmacologic agent indicated for treatment of non-compensated heart failure. Levosimendan enhances myocardial contractility without increasing myocardial oxygen consumption [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>] through two different mechanisms: (A) calcium-dependent binding to cardiac troponin C, thereby enhancing the calcium sensitivity of cardiac contractile proteins [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>] and improving myocardial contractility, and (B) opening of ATP-dependent potassium channels in vascular smooth muscle, resulting in venous, arterial and coronary vasodilation [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B8">8</xref>], thereby reducing myocardial preload and afterload.</p>
      <p>Levosimendan is 98% albumin-bound, its volume of distribution is 0.4 L/kg, plasma half life is 1 hour [<xref ref-type="bibr" rid="B9">9</xref>], and plasma clearance is 3 ml/kg/min [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Peak plasma concentrations occur 12 minutes after a bolus dose or 4 hours after starting a continuous infusion without a bolus. Levosimendan is extensively metabolized in the liver, is eliminated mainly by conjugation and excretion in urine and feces, and its elimination half-life is 1 hour [<xref ref-type="bibr" rid="B12">12</xref>]. After IV levosimendan administration, 5% of the drug is reduced in the small bowel to OR-1855, which is reabsorbed to the systemic circulation, and is then metabolized to OR-1896, which is pharmacologically active and produces a hemodynamic profile comparable to the parent-drug. OR-1896 is only 40% protein-bound, its peak plasma concentration is observed 1-4 days after levosimendan infusion ends [<xref ref-type="bibr" rid="B10">10</xref>], its half life is 80 hours, and it is responsible for the extended (7-9 days) duration of levosimendan clinical action [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>].</p>
      <p>Levosimendan is not dialyzable. In contrast, OR-1855 and OR-1896 are dialyzable, but their dialysis clearance is very slow (8-23 ml/minute). Consequently, the net effect of a 4-hour hemodialysis session on exposure to active metabolites is limited [<xref ref-type="bibr" rid="B3">3</xref>], and the AUCs for OR-1855 and OR-1896 are increased by 170% in hemodialysis patients. Although the Levosimendan package insert [<xref ref-type="bibr" rid="B3">3</xref>] states that levosimendan should not be used in ESRD patients, there is one case report of postoperative use [<xref ref-type="bibr" rid="B13">13</xref>], but no reports of intraoperative levosimendan use in hemodialysis patients. In this case report we describe a hemodialysis patient with severe CAD, ongoing myocardial ischemia despite maximal medical therapy, low LVEF and severe bilateral ICA stenosis. The patient received a 24-hour continuous IV levosimendan/norepinephrine infusion during and after OPCAB surgery, with very satisfactory results: myocardial contractility, CO, CI, SvO<sub>2 </sub>and INVOS markedly improved, and there was no hypotension or exacerbation of myocardial ischemia.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 63 year-old Caucasian man with unstable angina and chronic renal failure underwent one vessel OPCAB. Past medical history included smoking 2 packs per day for 40 years, hypertension, IDDM treated with insulin for 15 years, PVD with claudication and bilateral ICA stenosis, ESRD (Cr: 8.4 mg/dL, BUN: 199 mg/dL) which had been attributed to long-standing poorly controlled hypertension, and was treated with periodic (every other day) hemodialysis for 6 years, and sick sinus syndrome. He had a pacemaker (programmed in DDD mode with baseline HR set at 60/minute) inserted three years before this myocardial revascularization procedure, but the pacemaker was turned off immediately after anesthesia induction. He also had intermittent claudication, with preoperative angiography revealing significant right iliac and left femoral artery stenosis, extensive abdominal aorta calcification and 80% bilateral ICA stenosis. Coronary angiography revealed 3-vessel disease, with 80% mid-LAD stenosis, complete proximal and distal LCX occlusion with retrograde filling from the LAD, and complete ostial RCA occlusion. Transthoracic echocardiography revealed LV dilatation with akinetic basal inferior and basal posterior LV wall, hypokinetic medial posterior LV wall, LVEF estimated at 25-30%, moderate mitral regurgitation and pulmonary hypertension (estimated peak PA pressure 58 mmHg). In the last week before surgery, the patient had difficulty completing hemodialysis sessions due to serious hypotension, and experienced unstable angina, while under maximal medical therapy with nitrates (transdermal glyceryl trinitrate 10 mg per 24 hours), ACE inhibitors (p.o. enalapril 10 mg per day) and aspirin (p.o. 325 mg per day). Because of his unstable condition, we decided to proceed with myocardial revascularization only, and consider surgical treatment of bilateral ICA stenosis later. Furthermore, we chose the OPCAB technique, in order to lower the risk of adverse cerebral events and avoid the undesirable consequences of cardiopulmonary bypass. Monitoring included, in addition to the standard monitors mandated by the American Society of Anesthesiologists, invasive blood pressure through a right radial arterial line, CVP, PA and PAOP pressures through a PA catheter, which was inserted immediately after induction of anesthesia and was removed on the 2<sup>nd </sup>postoperative day. We also used INVOS (Cerebral Oximeter System, Somanetics), with sensors attached to the patient's forehead, to monitor adequacy of cerebral perfusion, and TEE to monitor myocardial contractility. Anesthesia induction was uneventful, without any hemodynamic derangement. Mean arterial pressure was maintained at 60 mmHg or higher, while the PA catheter revealed pulmonary hypertension (SPAP: 56 mmHg, PAOP: 18 mmHg, CVP: 18 mmHg, CO: 2.8 L/min, CI: 1.6 L/m<sup>2</sup>/min SvO<sub>2 </sub>49%, SVR 1114). As direct visualization of the heart confirmed severely impaired myocardial contractility with abnormal distension of both ventricles, we decided to start inotropic support using a combined levosimendan/norepinephrine infusion in an attempt to improve myocardial function and increase cardiac output, while avoiding myocardial ischemia and hypotension. The decision to use a levosimendan/norepinephrine combination was based on the need to (A) improve myocardial contractility and cardiac output without increasing myocardial oxygen consumption, and (B) avoid hypotension, which could aggravate myocardial and brain ischemia. Because of hypoalbuminemia, we started IV levosimendan infusion at only 0.07 &#x3BC;g/kg/min, while IV norepinephrine infusion started at 0.05 &#x3BC;g/kg/min and was titrated to effect. Baseline INVOS values were very low before anesthesia induction (42 on the left, 37 on the right side) and increased only slightly after anesthesia induction (45 on the left, 43 on the right side). However, thirty minutes after levosimendan infusion started, CO, CI and SvO<sub>2 </sub>improved significantly (to 3.6 L/min, 2.1 L/m<sup>2</sup>/min and 70% respectively), LVEF increased to 50% and INVOS also increased significantly (to 59 on the left, 53 on the right). Despite the need to gradually increase norepinephrine dose to 0.15 &#x3BC;g/kg/min, in order to maintain MAP &gt;60 mmHg, CI and SvO2 continued to rise, while CVP, PA and PAOP declined slightly over the ensuing 3 hours (while surgery was still underway), and this improvement persisted during the entire postoperative period (table <xref ref-type="table" rid="T1">1</xref>). Accidental intraoperative rupture of the very thin anterior RV wall resulted in hemodynamic collapse, requiring prompt, rapid administration of 5 units of red blood cells, 2 units of FFP and addition of epinephrine infusion at 0.07 &#x3BC;g/kg/min. Hypotension lasted approximately 30 minutes, until the RV wall rupture was securely corrected (without requiring extracorporeal circulation). Postoperatively, the patient was transferred to the ICU, where levosimendan infusion continued for 24 hours and norepinephrine continued for 40 hours. The patient was extubated on POD 1, and had uneventful hemodialysis a few hours after extubation. Detailed postoperative neurologic examination did not reveal any neurologic deficits. Vital signs remained stable postoperatively, except for an episode of hypotension shortly after hemodialysis on POD 5. This hypotensive event resolved with volume loading, and was attributed to pericardial effusion, which delayed discharge from the hospital until POD 12. Three months later, the patient was in good condition, had a normal life and continued hemodialysis three times/week without any problems. Follow-up echocardiography 4 months after the operation showed somewhat improved myocardial contractility, with LVEF estimated at 40%, mild mitral regurgitation and estimated peak pulmonary artery pressure at 35 mmHg. Now, three years later, he is still alive and doing remarkably well.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Hemodynamic and INVOS data</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th/>
              <th align="center">T<sub>1</sub></th>
              <th align="center">T<sub>2</sub></th>
              <th align="center">T<sub>3</sub></th>
              <th align="center">T<sub>4</sub></th>
              <th align="center">T<sub>5</sub></th>
              <th align="center">T<sub>6</sub></th>
              <th align="center">T<sub>7</sub></th>
              <th align="center">T<sub>8</sub></th>
              <th align="center">T<sub>9</sub></th>
              <th align="center">T<sub>10</sub></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left">HR</td>
              <td align="center">60</td>
              <td align="center">62</td>
              <td align="center">64</td>
              <td align="center">64</td>
              <td align="center">61</td>
              <td align="center">64</td>
              <td align="center">65</td>
              <td align="center">66</td>
              <td align="center">63</td>
              <td align="center">68</td>
            </tr>
            <tr>
              <td align="left">P<sub>syst</sub></td>
              <td align="center">100</td>
              <td align="center">125</td>
              <td align="center">104</td>
              <td align="center">113</td>
              <td align="center">108</td>
              <td align="center">97</td>
              <td align="center">101</td>
              <td align="center">110</td>
              <td align="center">91</td>
              <td align="center">106</td>
            </tr>
            <tr>
              <td align="left">P<sub>diast</sub></td>
              <td align="center">45</td>
              <td align="center">71</td>
              <td align="center">51</td>
              <td align="center">61</td>
              <td align="center">58</td>
              <td align="center">52</td>
              <td align="center">51</td>
              <td align="center">58</td>
              <td align="center">48</td>
              <td align="center">55</td>
            </tr>
            <tr>
              <td align="left">MAP</td>
              <td align="center">57</td>
              <td align="center">91</td>
              <td align="center">61</td>
              <td align="center">80</td>
              <td align="center">76</td>
              <td align="center">69</td>
              <td align="center">70</td>
              <td align="center">83</td>
              <td align="center">67</td>
              <td align="center">70</td>
            </tr>
            <tr>
              <td align="left">CVP</td>
              <td align="center">18</td>
              <td align="center">18</td>
              <td align="center">17</td>
              <td align="center">16</td>
              <td align="center">16</td>
              <td align="center">14</td>
              <td align="center">15</td>
              <td align="center">12</td>
              <td align="center">10</td>
              <td align="center">10</td>
            </tr>
            <tr>
              <td align="left">PAP<sub>syst</sub></td>
              <td align="center">56</td>
              <td align="center">48</td>
              <td align="center">46</td>
              <td align="center">46</td>
              <td align="center">44</td>
              <td align="center">44</td>
              <td align="center">40</td>
              <td align="center">39</td>
              <td align="center">31</td>
              <td align="center">35</td>
            </tr>
            <tr>
              <td align="left">PAP<sub>diast</sub></td>
              <td align="center">25</td>
              <td align="center">18</td>
              <td align="center">17</td>
              <td align="center">17</td>
              <td align="center">17</td>
              <td align="center">19</td>
              <td align="center">20</td>
              <td align="center">17</td>
              <td align="center">19</td>
              <td align="center">17</td>
            </tr>
            <tr>
              <td align="left">PAP<sub>mean</sub></td>
              <td align="center">37</td>
              <td align="center">30</td>
              <td align="center">30</td>
              <td align="center">30</td>
              <td align="center">25</td>
              <td align="center">25</td>
              <td align="center">26</td>
              <td align="center">23</td>
              <td align="center">24</td>
              <td align="center">24</td>
            </tr>
            <tr>
              <td align="left">PAOP</td>
              <td/>
              <td align="center">18</td>
              <td align="center">17</td>
              <td align="center">16</td>
              <td align="center">16</td>
              <td align="center">16</td>
              <td align="center">16</td>
              <td align="center">16</td>
              <td align="center">16</td>
              <td align="center">15</td>
            </tr>
            <tr>
              <td align="left">CO</td>
              <td align="center">2.8</td>
              <td align="center">3.6</td>
              <td align="center">4.1</td>
              <td align="center">4.2</td>
              <td align="center">4.0</td>
              <td align="center">4.6</td>
              <td align="center">4.3</td>
              <td align="center">4.6</td>
              <td align="center">4.6</td>
              <td align="center">4.6</td>
            </tr>
            <tr>
              <td align="left">CI</td>
              <td align="center">1.6</td>
              <td align="center">2.1</td>
              <td align="center">2.4</td>
              <td align="center">2.4</td>
              <td align="center">2.0</td>
              <td align="center">2.7</td>
              <td align="center">2.5</td>
              <td align="center">2.7</td>
              <td align="center">2.7</td>
              <td align="center">2.7</td>
            </tr>
            <tr>
              <td align="left">SVR</td>
              <td align="center">1114</td>
              <td align="center">1622</td>
              <td align="center">858</td>
              <td align="center">1219</td>
              <td align="center">1200</td>
              <td align="center">956</td>
              <td align="center">1023</td>
              <td align="center">1234</td>
              <td align="center">991</td>
              <td align="center">1043</td>
            </tr>
            <tr>
              <td align="left">PVR</td>
              <td/>
              <td align="center">266</td>
              <td align="center">253</td>
              <td align="center">266</td>
              <td align="center">180</td>
              <td align="center">156</td>
              <td align="center">186</td>
              <td align="center">121</td>
              <td align="center">139</td>
              <td align="center">156</td>
            </tr>
            <tr>
              <td align="left">LVEF</td>
              <td align="center">25</td>
              <td/>
              <td/>
              <td align="center">40</td>
              <td align="center">40</td>
              <td/>
              <td/>
              <td/>
              <td/>
              <td/>
            </tr>
            <tr>
              <td align="left">SvO<sub>2</sub></td>
              <td align="center">49</td>
              <td align="center">70</td>
              <td align="center">80</td>
              <td align="center">80</td>
              <td align="center">82</td>
              <td align="center">82</td>
              <td align="center">80</td>
              <td align="center">60</td>
              <td align="center">65</td>
              <td align="center">58</td>
            </tr>
            <tr>
              <td align="left">INVOS<sub>Left</sub></td>
              <td align="center">45</td>
              <td align="center">59</td>
              <td align="center">59</td>
              <td align="center">55</td>
              <td align="center">60</td>
              <td align="center">60</td>
              <td/>
              <td/>
              <td/>
              <td/>
            </tr>
            <tr>
              <td align="left">FiO<sub>2</sub></td>
              <td align="center">0.5</td>
              <td align="center">0.5</td>
              <td align="center">0.5</td>
              <td align="center">0.5</td>
              <td align="center">0.5</td>
              <td align="center">0.6</td>
              <td align="center">0.6</td>
              <td align="center">0.4</td>
              <td align="center">0.4</td>
              <td align="center">0.21</td>
            </tr>
            <tr>
              <td align="left">Norepinephrine*</td>
              <td/>
              <td align="center">0.05</td>
              <td align="center">0.08</td>
              <td align="center">0.12</td>
              <td align="center">0.15</td>
              <td align="center">0.12</td>
              <td align="center">0.15</td>
              <td align="center">0.2</td>
              <td align="center">0.08</td>
              <td align="center">0.02</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>* Dose in &#x3BC;g/kg/min</p>
          <p>HR in beats/minute</p>
          <p>P<sub>syst, </sub>P<sub>diast, </sub>P <sub>mean, </sub>CVP, PAP<sub>syst, </sub>PAP<sub>diast, </sub>PAP<sub>mean, </sub>PCWP, all measured in mmHg</p>
          <p>CO = L/min, CI = L/m<sup>2</sup>/min S<sub>V</sub>O<sub>2 </sub>= %, INVOS = %</p>
          <p>T<sub>1 </sub>before levosimendan/norepinephrine infusion started</p>
          <p>T<sub>2 </sub>1 h after levosimendan infusion started</p>
          <p>T<sub>3</sub>, T<sub>4 </sub>2 and 3 hours after levosimendan infusion started</p>
          <p>T<sub>5 </sub>at end of surgery</p>
          <p>T<sub>6 </sub>T<sub>7 </sub>6 and 12 hours after surgery</p>
          <p>T<sub>8, </sub>T<sub>9, </sub>T<sub>10 </sub>18, 24, 36 hours after surgery</p>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec>
      <title>Conclusions</title>
      <p>Levosimendan is a newer therapeutic agent for treatment of cardiac failure [<xref ref-type="bibr" rid="B13">13</xref>], is generally well tolerated, and its main side effects are usually due to vasodilation. Although levosimendan has been administered to patients with mild to moderate renal disease without serious adverse consequences [<xref ref-type="bibr" rid="B14">14</xref>], we could find only one published case of postoperative (but not intraoperative) levosimendan administration in a hemodialysis patient [<xref ref-type="bibr" rid="B13">13</xref>]. Despite the absence of published data, we decided to use levosimendan in our patient, because he had significantly impaired LV function, low CO, CI and SvO<sub>2</sub>, and evidence of impaired cerebral oxygenation, as measured by INVOS. We therefore needed to improve myocardial contractility, CO, CI and SvO<sub>2 </sub>without increasing myocardial oxygen consumption and without hypotension, which could be detrimental, due to severe bilateral ICA stenosis. Under the circumstances, combined levosimendan/norepinephrine use was a reasonable choice: levosimendan improves myocardial contractility without increasing myocardial oxygen consumption [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>], while norepinephrine has desirable inotropic and vasopressor properties. Use of IABP could also be a reasonable option, but insertion of IABP in this particular patient would be problematic due to extensive peripheral arterial (aortic, iliac and femoral) calcification and stenosis, and could further compromise lower extremity circulation. Dobutamine, milrinone and/or epinephrine could also improve myocardial contractility, but would likely increase myocardial oxygen consumption, and thereby exacerbate myocardial ischemia. In our case, the levosimendan/norepineprhine combination worked as predicted, conferred significant hemodynamic improvement (despite unexpected surgical complications necessitating rapid intraoperative RBC and FFP transfusion) and facilitated completion of the OPCAB procedure without need for extracorporeal circulation. Thus the patient benefitted from improved myocardial contractility, increased CO, CI and SvO<sub>2 </sub>and reduced CVP and PAOP, and these beneficial changes lasted for several days after levosimendan infusion stopped. We believe that the effectiveness of levosimendan at this low dose (0.07 &#x3BC;g/kg/min) was due to reduced protein binding because of hypoalbuminemia (albumin plasma level was 3.1 mg/dL in this case). In addition, the use of a low levosimendan dose, the combination with norepinephrine and close monitoring, in an attempt to avoid or promptly treat hypotension, all likely contributed to hemodynamic stability in this case. In conclusion, this case report suggests that combined levosimedan/norepinephrine IV infusion is a reasonable inotropic support option in patients with heart failure and ongoing myocardial ischemia, even in the presence of end-stage renal disease and severe bilateral internal carotid artery stenosis.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>ACE inhibitors: Angiotensin-Converting Enzyme Inhibitors; ATP: Adenosine Tri-Phospate; CABG: Coronary Artery Bypass Grafting; CAD: Coronary Artery Disease; CI: Cardiac Index; CO: Cardiac Output; CRF: Chronic Renal Failure; CVP: Central Venous Pressure; ESRD: End-Stage Renal Disease; FFP: Fresh Frozen Plasma; HR: Heart Rate; IABP: Intra-Aortic Balloon Pump; ICA: Internal Carotid Artery; IDDM: Insulin-Dependent Diabetes Mellitus; INVOS: IN Vivo Optical Spectroscopy; IV: Intravenous; LAD: Left Anterior Descending; LCX: Left Circumflex Coronary Artery; LV: Left Ventricle; LVEF: Left-ventricular ejection fraction; MAP: Mean Arterial Pressure; OPCAB: Off pump coronary artery by-pass; PA: Pulmonary Artery; PAOP: Pulmonary Artery Occlusion Pressure; POD: Postoperative Day; PVD: Peripheral Vascular Disease; RBC: Red Blood Cells; RCA: Right Coronary Artery; RV: Right Ventricle; SvO<sub>2</sub>: Mixed Venous Oxygen Saturation; TEE: Trans-Esophageal Echocardiography.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>This work was supported solely by department funds. All authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>GP supervised intraoperative and postoperative anesthesia care, conceived the study and revised manuscript, NB assisted with the operation, participated in postoperative patient care and collected data, PT provided intraoperative and postoperative anesthesia care and collected data, SN performed the operation, directed postoperative care and revised manuscript, MK did data interpretation, wrote and revised manuscript. All authors have read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Todaka</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Yi</surname>
            <given-names>GH</given-names>
          </name>
          <name>
            <surname>Stennett</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Knecht</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Packer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Burkhoff</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Effects of levosimendan on myocardial contractility and oxygen consumption</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>1996</year>
          <volume>279</volume>
          <fpage>120</fpage>
          <lpage>127</lpage>
          <pub-id pub-id-type="pmid">8858984</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Levijoki</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Pollesello</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kaivola</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Tilgmann</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Sorsa</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Annila</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kilpelainen</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Haikala</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan</article-title>
          <source>J Mol Cell Cardiol</source>
          <year>2000</year>
          <volume>32</volume>
          <fpage>479</fpage>
          <lpage>491</lpage>
          <pub-id pub-id-type="doi">10.1006/jmcc.1999.1093</pub-id>
          <pub-id pub-id-type="pmid">10731446</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="book">
          <source>Simdax - Levosimendan 2.5 mg/mL injection concentrate - Data Sheet</source>
          <year>2009</year>
          <publisher-name>New Zealand, New Zealand Medicines and Medical Devices Safety Authority, a Business Unit of the Ministry of Health</publisher-name>
          <ext-link ext-link-type="uri" xlink:href="http://www.medsafe.govt.nz/profs/Datasheet/s/Simdaxinj.htm">http://www.medsafe.govt.nz/profs/Datasheet/s/Simdaxinj.htm</ext-link>
          <comment>1-10-2010.</comment>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mebazaa</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Nieminen</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Packer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cohen-Solal</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kleber</surname>
            <given-names>FX</given-names>
          </name>
          <name>
            <surname>Pocock</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Thakkar</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Padley</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Poder</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kivikko</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial</article-title>
          <source>JAMA</source>
          <year>2007</year>
          <volume>297</volume>
          <fpage>1883</fpage>
          <lpage>1891</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.297.17.1883</pub-id>
          <pub-id pub-id-type="pmid">17473298</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bowman</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Haikala</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Paul</surname>
            <given-names>RJ</given-names>
          </name>
          <article-title>Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>1999</year>
          <volume>288</volume>
          <fpage>316</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="pmid">9862786</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Keheninen</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Haikala</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Increases in diastolic coronary flow by Levosimendan and pinacidil are differently mediated through opening of the ATP-sensitive potassium channels</article-title>
          <source>J Amer Coll Cardiol</source>
          <year>1998</year>
          <volume>31</volume>
          <fpage>154</fpage>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pataricza</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hohn</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Petri</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Balogh</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Papp</surname>
            <given-names>JG</given-names>
          </name>
          <article-title>Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein</article-title>
          <source>J Pharm Pharmacol</source>
          <year>2000</year>
          <volume>52</volume>
          <fpage>213</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="doi">10.1211/0022357001773715</pub-id>
          <pub-id pub-id-type="pmid">10714952</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Yokoshiki</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Katsube</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Sunagawa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sperelakis</surname>
            <given-names>N</given-names>
          </name>
          <article-title>The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>1997</year>
          <volume>283</volume>
          <fpage>375</fpage>
          <lpage>383</lpage>
          <pub-id pub-id-type="pmid">9336346</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kivikko</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lehtonen</surname>
            <given-names>L</given-names>
          </name>
          <article-title>Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure</article-title>
          <source>Curr Pharm Des</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>435</fpage>
          <lpage>455</lpage>
          <pub-id pub-id-type="doi">10.2174/1381612053382043</pub-id>
          <pub-id pub-id-type="pmid">15725064</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Puttonen</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kantele</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ruck</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ramela</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hakkinen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kivikko</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pentikainen</surname>
            <given-names>PJ</given-names>
          </name>
          <article-title>Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment</article-title>
          <source>J Clin Pharmacol</source>
          <year>2008</year>
          <volume>48</volume>
          <fpage>445</fpage>
          <lpage>454</lpage>
          <pub-id pub-id-type="doi">10.1177/0091270007313390</pub-id>
          <pub-id pub-id-type="pmid">18303124</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Antila</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kivikko</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lehtonen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Eha</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Heikkila</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pohjanjousi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Pentikainen</surname>
            <given-names>PJ</given-names>
          </name>
          <article-title>Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan</article-title>
          <source>Br J Clin Pharmacol</source>
          <year>2004</year>
          <volume>57</volume>
          <fpage>412</fpage>
          <lpage>415</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2125.2003.02043.x</pub-id>
          <pub-id pub-id-type="pmid">15025738</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>McLean</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Nalos</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ting</surname>
            <given-names>I</given-names>
          </name>
          <article-title>Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide</article-title>
          <source>J Cardiovasc Pharmacol</source>
          <year>2005</year>
          <volume>46</volume>
          <fpage>830</fpage>
          <lpage>835</lpage>
          <pub-id pub-id-type="doi">10.1097/01.fjc.0000189076.71730.f1</pub-id>
          <pub-id pub-id-type="pmid">16306809</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Raftopoulos</surname>
            <given-names>SC</given-names>
          </name>
          <article-title>Levosimendan following coronary artery bypass grafting in a patient with end-stage renal failure: a case report</article-title>
          <source>Crit Care Resusc</source>
          <year>2004</year>
          <volume>6</volume>
          <fpage>109</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="pmid">16566697</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="other">
          <name>
            <surname>Sandell</surname>
            <given-names>EP</given-names>
          </name>
          <name>
            <surname>Antila</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Koistinen</surname>
            <given-names>IL</given-names>
          </name>
          <article-title>The effects of renal failure on the pharmacokinetics of levosimendan [abstract]</article-title>
          <source>1st Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT)</source>
          <year>1995</year>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Antila</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Honkanen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Lehtonen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Neuvonen</surname>
            <given-names>PJ</given-names>
          </name>
          <article-title>The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan</article-title>
          <source>Int J Clin Pharmacol Ther</source>
          <year>1998</year>
          <volume>36</volume>
          <fpage>446</fpage>
          <lpage>449</lpage>
          <pub-id pub-id-type="pmid">9726699</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Haikala</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kaivola</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nissinen</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Wall</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Levijoki</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Linden</surname>
            <given-names>IB</given-names>
          </name>
          <article-title>Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan</article-title>
          <source>J Mol Cell Cardiol</source>
          <year>1995</year>
          <volume>27</volume>
          <fpage>1859</fpage>
          <lpage>1866</lpage>
          <pub-id pub-id-type="doi">10.1016/0022-2828(95)90009-8</pub-id>
          <pub-id pub-id-type="pmid">8523447</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lehtonen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Mills-Owens</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Akkila</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Safety of levosimendan and other calcium sensitizers</article-title>
          <source>J Cardiovasc Pharmacol</source>
          <year>1995</year>
          <volume>26</volume>
          <issue>Suppl 1</issue>
          <fpage>S70</fpage>
          <lpage>S76</lpage>
          <pub-id pub-id-type="pmid">8907134</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
